EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study

Alexandra M Blossey, Sina Brückner, Marcus May, Gerald P Parzmair, Hitt Sharma, Umesh Shaligram, Leander Grode, Stefan H E Kaufmann, Mihai G Netea, Christoph Schindler

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac881 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Alexandra M Blossey und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vakzine Projekt Management GmbH, Hannover, Germany. Hauptthemen laut MEDLINE: BCG Vaccine, COVID-19. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Serum Institute of India Pvt Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bacille Calmette-Guérin (BCG) vaccination can potentially reduce the rate of respiratory infections in vulnerable populations. This study evaluates the safety and efficacy of VPM1002 (a genetically modified BCG) as prophylaxis against severe respiratory tract infections including coronavirus disease 2019 (COVID-19) in an elderly population.

Methods

In this phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trial, healthy elderly volunteers (N = 2064) were enrolled, randomized (1:1) to receive either VPM1002 or placebo, and followed up remotely for 240 days. The primary outcome was the mean number of days with severe respiratory infections at hospital and/or at home. Secondary endpoints included the incidence of self-reported fever, number of hospital and intensive care unit (ICU) admissions, and number of adverse events.

Results

A total of 31 participants in the VPM1002 group reported at least 1 day with severe respiratory disease and a mean number of days with severe respiratory disease of 9.39 ± 9.28 while in the placebo group; 38 participants reported a mean of 14.29 ± 16.25 days with severe respiratory disease. The incidence of self-reported fever was lower in the VPM1002 group (odds ratio, 0.46 [95% confidence interval, .28–.74]; P = .001), and consistent trends to fewer hospitalization and ICU admissions due to COVID-19 were observed after VPM1002 vaccination. Local reactions typical for BCG were observed in the VPM1002-vaccinated group, which were mostly of mild intensity.

Conclusions

Vaccination with VPM1002 is well tolerated and seems to have a prophylactic effect against severe respiratory disease in the elderly. Clinical Trials Registration NCT04435379.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BCG VaccineCOVID-19AgedHumansDouble-Blind MethodHospitalizationSARS-CoV-2Respiratory Tract DiseasesMiddle AgedAged, 80 and overMaleFemaleTime FactorsPatient Acuity

Stichwörter der Autor:innen

COVID-19SARS-CoV-2VPM1002respiratory tract infectionstrained immunity

Substanzen

BCG VaccineVPM1002 recombinant BCG vaccine

Autor:innen und Institutionen

  • Vakzine Projekt Management GmbH, Hannover, Germany.
  • Serum Institute of India Private Limited, Pune, India.
  • Max Planck Institute for Infection Biology, Berlin, Germany.
  • Hagler Institute for Advanced Study, Texas A&M University, College Station, Texas, USA.
  • Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
  • Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Förderung

  • Serum Institute of India Pvt Ltd

Zitieren

APA

Blossey, A. M., Brückner, S., May, M., Parzmair, G. P., Sharma, H., Shaligram, U., Grode, L., Kaufmann, S. H. E., Netea, M. G., & Schindler, C. (2023). VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac881

Vancouver

Blossey AM, Brückner S, May M, Parzmair GP, Sharma H, Shaligram U, et al. VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac881

BibTeX
@article{Blossey2023,
  author = {Blossey, Alexandra M and Brückner, Sina and May, Marcus and Parzmair, Gerald P and Sharma, Hitt and Shaligram, Umesh and Grode, Leander and Kaufmann, Stefan H E and Netea, Mihai G and Schindler, Christoph},
  title = {VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac881}
}
Kostenlos starten →